253 related articles for article (PubMed ID: 11011805)
1. Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: implications for management of vascular disorders.
Mousa SA
Semin Thromb Hemost; 2000; 26 Suppl 1():39-46. PubMed ID: 11011805
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists.
Mousa SA; Khurana S; Forsythe MS
Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):1162-7. PubMed ID: 10764688
[TBL] [Abstract][Full Text] [Related]
3. Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans.
Mousa SA; Bozarth JM; Seiffert D; Feuerstein GZ
Blood Coagul Fibrinolysis; 2005 Apr; 16(3):165-71. PubMed ID: 15795533
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effect of different platelet GPIIb/IIa antagonists on the dynamics of platelet/fibrin-mediated clot strength induced using thromboelastography.
Mousa SA; Forsythe MS
Thromb Res; 2001 Oct; 104(1):49-56. PubMed ID: 11583738
[TBL] [Abstract][Full Text] [Related]
5. Differential efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet/fibrin-mediated clot dynamics under different conditions using thrombelastography: the critical need for anticoagulant.
Mousa SA; Forsythe MS; Bozarth JM
Coron Artery Dis; 2002 Jun; 13(4):243-8. PubMed ID: 12193852
[TBL] [Abstract][Full Text] [Related]
6. Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography.
Khurana S; Mattson JC; Westley S; O'Neill WW; Timmis GC; Safian RD
J Lab Clin Med; 1997 Oct; 130(4):401-11. PubMed ID: 9358079
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of anticoagulants and platelet inhibitors in cancer-induced thrombosis.
Cloonan ME; DiNapoli M; Mousa SA
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):341-5. PubMed ID: 17473575
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis.
Mousa SA; Abulencia JP; McCarty OJ; Turner NA; Konstantopoulos K
J Cardiovasc Pharmacol; 2002 Apr; 39(4):552-60. PubMed ID: 11904529
[TBL] [Abstract][Full Text] [Related]
9. In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography.
Mousa SA
Blood Coagul Fibrinolysis; 2007 Jan; 18(1):55-60. PubMed ID: 17179828
[TBL] [Abstract][Full Text] [Related]
10. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
Cohen M
Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
[TBL] [Abstract][Full Text] [Related]
11. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
Mousa SA; Bozarth JM; Forsythe MS; Slee A
Cardiovasc Res; 2000 Sep; 47(4):819-26. PubMed ID: 10974231
[TBL] [Abstract][Full Text] [Related]
12. Regulation of clot retraction by glycoprotein IIb/IIIa antagonists.
Seiffert D; Pedicord DL; Kieras CJ; He B; Stern AM; Billheimer JT
Thromb Res; 2002 Nov; 108(2-3):181-9. PubMed ID: 12590956
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist.
Ahmad S; Jeske WP; Ma Q; Walenga JM; Fareed J
Thromb Res; 2001 Apr; 102(2):143-51. PubMed ID: 11323025
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.
Klinkhardt U; Graff J; Westrup D; Kirchmaier CM; Esslinger HU; Breddin HK; Harder S
Br J Clin Pharmacol; 2001 Sep; 52(3):297-305. PubMed ID: 11560562
[TBL] [Abstract][Full Text] [Related]
15. An update on heparins at the beginning of the new millennium.
Fareed J; Hoppensteadt DA; Bick RL
Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802
[TBL] [Abstract][Full Text] [Related]
16. Management of thrombotic and cardiovascular disorders in the new millenium.
Fareed J; Hoppensteadt DA; Bick RL
Clin Appl Thromb Hemost; 2003 Apr; 9(2):101-8. PubMed ID: 12812377
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.
Wang X; Dorsam RT; Lauver A; Wang H; Barbera FA; Gibbs S; Varon D; Savion N; Friedman SM; Feuerstein GZ
J Pharmacol Exp Ther; 2002 Dec; 303(3):1114-20. PubMed ID: 12438534
[TBL] [Abstract][Full Text] [Related]
18. Glycoprotein IIb/IIIa inhibitors and low-molecular-weight heparins: a combined role in coronary interventions?
Fry ET
Clin Cardiol; 2001 Mar; 24(3 Suppl):I8-11. PubMed ID: 11286313
[TBL] [Abstract][Full Text] [Related]
19. Low molecular weight heparins and glycoprotein IIb/IIIa antagonists.
Ferguson JJ
J Interv Cardiol; 2002 Apr; 15(2):147-54. PubMed ID: 12063810
[TBL] [Abstract][Full Text] [Related]
20. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
